Here are six highlights:
1. SeaSpine predicts revenue to hit between $34 million and $34.2 million for the second quarter of 2017, reflecting a 3 percent increase over the same period the year prior.
2. The company’s spinal instrumentation revenue will likely be $16.6 million for the second quarter of 2016 and the orthobiologics revenue will likely be around $17.6 million.
3. U.S. revenue will likely see a 1 percent boost over the second quarter of 2017 to $30.4 million.
4. U.S. spinal instrumentation revenue will decrease about 5 percent and orthobiologics revenue will likely increase 7.5 percent over the second quarter of 2017.
5. SeaSpine’s cash and cash equivalents will likely be around $12.3 million.
6. The company saw $4.6 million in net proceed in the second quarter of 2017, via the sale of about 477,000 shares of its common stock.
More articles on devices:
Orthopedic trauma devices market projects 7.2% CAGR: 6 takeaways
Providence Medical Technology reports outcomes from 2 studies on DTRAX Expandable Cage: 5 notes
InVivo Therapeutics welcomes Dr. Richard Toselli as CMO: 4 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
